Table 2.
The Primary and Secondary Outcomes in the Postpropensity Score-Matched Cohorts
| Primary Outcomes | ||||||
|---|---|---|---|---|---|---|
| Nirmatrelvir-Ritonavir Cohort |
Untreated Control Cohort |
|||||
| N (%) | 95% CI* | N (%) | 95% Cl* | Difference in % with 95% CI* | P value | |
| Composite outcome within 30 days of enrollment | 52 (0.9) | 0.7, 1.2 | 122 (2.1) | 1.8, 2.5 | −1.2 (−1.7, −0.8) | <.01 |
| All-cause hospitalization within 30 days of enrollment | 50 (0.9) | 0.6, 1.1 | 118 (2.1) | 1.7, 2.5 | −1.2 (−1.6, −0.7) | <.01 |
| Mortality within 30 days of enrollment | 2 (0.0) | 0.0, 0.0 | 6 (0.1) | 0.0, 0.2 | −0.1 (−0.2, 0.0) | .29 |
| Secondary Outcomes | ||||||
|---|---|---|---|---|---|---|
| Nirmatrelvir-Ritonavir Cohort |
Untreated Control Cohort |
|||||
| N (%) | 95% CI* | N (%) | 95% Cl* | Difference in % with 95% CI* | P value | |
| Emergency visit within 30 days of index date | 158 (2.7) | 2.3, 3.2 | 213 (3.7) | 3.2, 4.2 | −1.0 (−1.6, −0.3) | <.01 |
CI = confidence interval.
⁎
The Clopper-Pearson method was used to calculate 95% CIs for the outcome percentages using the R package (Exactci). CI for difference in paired proportions between the treatment and control cohorts.